Core Viewpoint - The article discusses the successful IPO of Nanjing Weilizhibo Biotechnology Co., Ltd. on the Hong Kong Stock Exchange, highlighting the strong interest from both retail and institutional investors, which reflects confidence in the company's innovative drug pipeline and commercialization potential [3][5][30]. Company Overview - Weilizhibo officially listed on the Hong Kong Stock Exchange with the stock code 9887.HK, offering approximately 36.86 million shares at a price of HKD 35 per share [3]. - The company achieved a retail subscription rate of 3,494.8 times, setting a record for the Hong Kong 18A medical innovation sector, while institutional subscriptions reached 40.8 times, also a historical high [3][5]. Institutional Support - The IPO was sponsored by Morgan Stanley and CITIC Securities (Hong Kong), with nine cornerstone investors committing a total of USD 69 million (approximately HKD 542 million), including notable firms like OrbiMed, Tencent, and E Fund [5][7]. - The presence of leading medical investment funds among cornerstone investors indicates strong confidence in Weilizhibo's innovative drug pipeline and its potential for commercialization [5][9]. Product Pipeline and Technology - Weilizhibo's core product, LBL-024, is a unique targeted therapy that has reached critical clinical stages, demonstrating significant safety and efficacy in treating advanced neuroendocrine carcinoma [9][14]. - The company’s product pipeline includes one core product (LBL-024), three main products (LBL-034, LBL-033, LBL-007), and ten high-potential innovative candidates, showcasing a diverse approach to cancer treatment [11][19]. Clinical Development and Market Strategy - LBL-024 has received breakthrough therapy designation from the Chinese National Medical Products Administration and orphan drug designation from the U.S. FDA, validating its global development potential [10][15]. - The company plans to adopt a "self-research + cooperation" model for commercialization, targeting niche indications like EP-NEC before expanding to larger markets [20][23]. Financial Outlook - The funds raised from the IPO will primarily support the clinical development of LBL-024, with a focus on expanding its indications [23][24]. - The company’s R&D expenditure is projected to be CNY 1.857 billion in 2024, with a significant portion allocated to core product development, ensuring alignment with clinical timelines [23][24]. Market Potential - The global oncology immunotherapy market is expected to exceed USD 500 billion by 2025, positioning Weilizhibo strategically within a high-growth sector [25][30]. - The successful commercialization of LBL-024 could lead to a significant revaluation of the company's market potential, transforming it from a niche player to a key competitor in the global immunotherapy landscape [25][30].

Core Insights - The article presents the market capitalization rankings of the top 50 Chinese technology and internet companies as of July 25, 2025, highlighting their respective valuations in billions of dollars [1]. Group 1: Market Capitalization Rankings - The top three companies by market capitalization are: 1. Alibaba: $1,000.00 billion 2. Tencent: $800.00 billion 3. Baidu: $600.00 billion [3] - Other notable companies in the top 10 include: - JD.com: $482.47 billion - SMIC (Semiconductor Manufacturing International Corporation): $519.90 billion - Tencent Music: $328.83 billion [3][4] Group 2: Additional Rankings - Companies ranked from 11 to 20 include: - Li Auto: $316.74 billion - Xpeng Motors: $182.36 billion - NIO: $109.38 billion [4][5] - The rankings continue with companies such as: - New Oriental: $74.44 billion - Kingsoft: $61.55 billion - Perfect World: $38.92 billion [5]

Core Insights - The Hong Kong Stock Connect Non-Bank ETF (513750) has reached a record size of 10.364 billion yuan as of July 24, 2025, marking a year-to-date growth of 1213.56% [1] - The ETF has seen continuous net inflows over the past 17 days, with a total of 4.966 billion yuan in net inflows, and 5.897 billion yuan over the past month [1] - The ETF has achieved a 52.78% increase since its low point on April 10, 2025, and has a one-year net value increase of 90.63%, ranking in the top 1.36% among 2940 index stock funds [2] Fund Performance - The Hong Kong Stock Connect Non-Bank ETF recorded a trading volume of 2.158 billion yuan on July 24, 2025, with a turnover rate of 22.14%, indicating active market participation [2] - The ETF has a maximum monthly return of 31.47% since its inception, with the longest consecutive monthly gain being 4 months and an average monthly return of 7.04% [2] - The ETF closely tracks the CSI Hong Kong Stock Connect Non-Bank Financial Theme Index, which includes up to 50 listed companies that meet the non-bank financial theme criteria [2] Sector Analysis - The top ten weighted stocks in the CSI Hong Kong Stock Connect Non-Bank Financial Theme Index account for 77.92% of the index, with major holdings including China Ping An, AIA, and Hong Kong Exchanges and Clearing [3] - Market sentiment has improved in Q2 2025, leading to an increase in the non-bank sector's weight, with expectations for both fundamental and valuation improvements [3] - The insurance sector is expected to benefit from a stable interest rate environment and improved investment returns, which could enhance profitability [4]

Core Insights - The report highlights the rebound in global stock markets during Q2, with significant gains in US and German markets, raising concerns about potential pullbacks in Q3 due to high valuations and risk sentiment [2][8] - The report emphasizes the potential for a revaluation of the Hong Kong Stock Exchange (HKEX), with a projected PE range of 30 to nearly 70 times, driven by fundamentals and liquidity [10][12] - The analysis of the computer industry indicates a low fund allocation, suggesting opportunities for increasing investments in Hong Kong IT and financial sectors [12][14] Market Performance Summary - The Shanghai Composite Index closed at 3606 points, with a 1-day increase of 0.65% and a 5-day increase of 5.41% [1] - The Shenzhen Composite Index closed at 2203 points, with a 1-day increase of 1.19% and a 5-day increase of 8.89% [1] - Large-cap indices showed a 1-month increase of 6.22%, while small-cap indices outperformed with a 1-month increase of 9.14% [1] Industry Performance Summary - The energy metals sector experienced a significant 1-day increase of 7.55% and a 1-month increase of 19.66% [1] - The small metals sector saw a 1-month increase of 30.16%, indicating strong performance [1] - Conversely, the precious metals sector faced a 1-day decline of 2.19% and a 1-month increase of only 2.28% [1] Investment Opportunities - The report suggests that the HKEX is positioned for growth, with a projected net profit of HKD 165 billion, 179 billion, and 188 billion for 2025-2027, reflecting year-on-year growth rates of 26%, 9%, and 5% respectively [10][12] - The computer industry is highlighted for its potential growth, with AI remaining a key focus area, and a notable shift towards high-end products in the domestic market [12][14] - The photovoltaic industry is entering a new phase with policies aimed at reducing competition and improving pricing structures, which could lead to increased profitability for key players [14][16]

Group 1 - On July 24, 2025, SMIC (00981), Alibaba-W (09988), and Tencent Holdings (00700) ranked as the top three companies by trading volume in the southbound trading of the Stock Connect, with trading volumes of 4.395 billion, 3.061 billion, and 2.944 billion respectively [1] - In the southbound trading of the Shenzhen-Hong Kong Stock Connect, Tencent Holdings (00700), SMIC (00981), and Alibaba-W (09988) also ranked as the top three, with trading volumes of 2.138 billion, 1.961 billion, and 1.635 billion respectively [1] Group 2 - In the southbound trading of the Stock Connect, the top active companies included SMIC (00981) with a trading amount of 4.395 billion and a net buy of -0.684 billion, Alibaba-W (09988) with a trading amount of 3.061 billion and a net buy of -0.373 billion, and Tencent Holdings (00700) with a trading amount of 2.944 billion and a net buy of +0.381 billion [2] - In the southbound trading of the Shenzhen-Hong Kong Stock Connect, Tencent Holdings (00700) had a trading amount of 2.138 billion with a net buy of +0.158 billion, SMIC (00981) had a trading amount of 1.961 billion with a net buy of +0.667 billion, and Alibaba-W (09988) had a trading amount of 1.635 billion with a net buy of +0.178 billion [2]

智通财经APP获悉，7月24日港股市场，北水成交净买入37.19亿港元，其中港股通(沪)成交净买入21.52 亿港元，港股通(深)成交净买入15.67亿港元。 北水净买入最多的个股是腾讯(00700)、港交所(00388)、华虹半导体(01347)。北水净卖出最多的个股是 小米集团-W(01810)、阿里巴巴-W(09988)、华新水泥(06655)。 | 股票名称 | 买入额 | 卖出额 | 买卖总额 | | --- | --- | --- | --- | | | | | 净流入 | | 中芯国际 | 18.56亿 | 25.40亿 | 43.95亿 | | HK 00981 | | | -6.84 乙 | | 阿里巴巴-W | 13.44 Z | 17.17 乙 | 30.61亿 | | HK 09988 | | | -3.73 乙 | | 腾讯控股 | 16.63 亿 | 12.82 乙 | 29.44 Z | | HK 00700 | | | +3.81 乙 | | 美团-W | 11.75亿 | 11.79 乙 | 23.54亿 | | HK 03890 | | | -362.73万 | | 中国中 ...

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company is expected to experience verifiable growth, leading to a potential revaluation [1] - The current price-to-earnings (PE) ratio is 38 times, with an upward potential of 24% based on a target PE of 42 times, resulting in a reasonable market value of 692 billion HKD [6][7] - The company benefits from its monopoly status and integrated clearing platform, which allows it to earn commissions from Average Daily Turnover (ADT) [6][7] Financial Data and Earnings Forecast - Revenue projections (in million HKD) for the years 2023 to 2027 are as follows: - 2023: 20,516 (11% growth) - 2024: 22,374 (9% growth) - 2025E: 26,978 (21% growth) - 2026E: 29,020 (8% growth) - 2027E: 29,857 (3% growth) [4] - Net profit attributable to shareholders (in million HKD) is forecasted as: - 2023: 11,862 (18% growth) - 2024: 13,050 (10% growth) - 2025E: 16,477 (26% growth) - 2026E: 17,936 (9% growth) - 2027E: 18,775 (5% growth) [4] - Earnings per share (in HKD) are projected to be: - 2023: 9.36 - 2024: 10.29 - 2025E: 13.00 - 2026E: 14.15 - 2027E: 14.81 [4] Valuation Review - The valuation range for the company is estimated between 30 to 70 times PE, with fundamental and liquidity factors being the core drivers [6][19] - The report emphasizes that the company’s growth potential is supported by the increasing market capitalization of new economy sectors, which have risen from 17% in 2018 to 35% in 2025 YTD [6][59] - The report highlights that the ADT is a critical factor influencing the company's profitability, with expectations for ADT to remain robust due to increased connectivity between mainland China and Hong Kong [6][8]

金十数据7月24日讯，美银证券发布研报称，预期港交所(00388.HK)上半年纯利为80亿港元，较去年同 期上升31%。第二季日均成交额料维持在2,380亿港元的高水平(去年同期为1220亿港元)，支持强劲的交 易费收入和结算费收入。美银证券维持港交所全年盈利不变，并对明年和后年盈利预测上调6%至7%。 目标价由440港元升至520港元，相当于预测合并2025至2026年市盈率40倍，重申"买入"评级。 美银证券：升香港交易所目标价至520港元 重申"买入"评级 ...

Group 1 - The article presents the market capitalization rankings of the top 50 Chinese technology and internet companies as of July 24, 2025 [1] - The highest-ranked company is Alibaba, with a market capitalization of 1,000 billion [3] - Other notable companies in the top 10 include Tencent with 600 billion and Baidu with 320 billion [3][4] Group 2 - The rankings show significant market values, with companies like JD.com at 489.1 billion and Kuaishou at 431.56 billion [3] - The list includes various sectors such as e-commerce, automotive, and software, indicating a diverse technology landscape [4][5] - Companies like Xpeng Motors and NIO are also featured, with market caps of 179.5 billion and 111.42 billion respectively [3][4]

Core Viewpoint - Hong Kong's equity financing market achieved the highest new stock financing amount globally in the first half of 2025, driven by improved investor sentiment and a significant influx of quality companies seeking funds [3][4]. Group 1: Market Performance - In the first half of 2025, Hong Kong's new stock financing reached $14.1 billion, a 695% increase compared to the same period in 2024, significantly outpacing the global new stock financing growth of 8% [4]. - The average daily trading volume in Hong Kong increased by 82% year-on-year to HKD 240 billion, with the Hang Seng Index rising over 20% [3]. Group 2: Major Listings - Notable large IPOs included CATL, which raised $5.3 billion, marking the largest IPO globally since 2023. Other significant listings included Heng Rui Pharmaceutical, Hai Tian Flavoring, and Sanhua Intelligent Control, each raising over $1 billion [9]. - Hong Kong secured four positions in the global top ten IPOs for the first half of 2025, with these companies averaging a 14% increase in stock price since their listings [9]. Group 3: A+H Listings and International Companies - Eight A-share companies raised a total of $10.1 billion by listing in Hong Kong, primarily to expand their international presence. The H-shares of these companies generally traded at a smaller discount compared to A-shares, indicating strong international investor demand [11]. - International companies like IFBH and Mi Rui Group successfully listed in Hong Kong, enhancing the city's appeal as an international financing hub [11]. Group 4: Investor Participation - The new stocks issued in the first half of 2025 saw active participation from international institutional investors, including long-term funds, private equity, strategic investors, hedge funds, and sovereign wealth funds from North America, Europe, and the Middle East [13]. - Retail investors also showed strong interest, leading to record-high demand for new stocks, with some experiencing oversubscription [14]. Group 5: Sector Performance - The healthcare sector saw a total equity financing of $5.8 billion, the highest for the first half of the year since 2021. The TMT sector, driven by AI innovations, raised $13.7 billion, while the consumer sector, particularly in new stock listings, saw an average stock price increase of 70% [16]. Group 6: Market Optimization Measures - Regulatory measures, such as the "Tech Company Fast Track" launched in May 2025, have expedited the listing process for tech and biotech companies. The momentum continued into July, with eight companies successfully listing in the first two weeks [20].